PIK3CA and breast cancer: Compared with other kinds of PI3K inhibitors, GDC-0941, an orally bioavailable inhibitor of class I PI3K, displays more favorable pharmacokinetic and toxicological properties [27] and is now in clinical development for many tumors including breast cancer [27–29].